CoChat

Plasmodium vivax relapse reservoirs in Ethiopia: microhaplotype sequencing informs recurrent infection origins

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; none of the 71 sources its claims cite is checked for support yet.

Abstract

Determining the origin of recurrent Plasmodium vivax infections is critical for quantifying the public health burden of the hypnozoite reservoir, understanding transmission potential, and evaluating anti-relapse antimalarial efficacy. In Ethiopia, P. vivax is a major contributor to malaria burden, but the relative contribution of relapse to recurrent infections remains poorly quantified. We performed microhaplotype genotyping using a panel of 93 genome-wide markers and applied a probabilistic recurrence classification framework to recurrent P. vivax samples collected in two Ethiopian radical cure trials (IMPROV and OPRA). Genotyping was conducted on parasite isolates collected at enrolment and subsequent recurrences, with participants monitored over a 12-month follow-up period (IMPROV: 604 samples from 444 participants; OPRA: 621 samples from 342 participants). Recurrent infections were classified using a Bayesian hierarchical model implemented in Pv3Rs , which estimated marginal posterior probabilities of relapse, reinfection, or recrudescence based on genotyping data and background population dynamics. Priors were structured across biologically motivated time windows reflecting the natural history of P. vivax infection in Ethiopia and anticipated drug efficacy. Recurrences with a probability of relapse (p(L)) ≥ 0.75 were classified as relapses. In the absence of primaquine, probable relapse was the dominant classification for primary recurrent infections in both trials (75.5%; 102/135) and for consecutive recurrent infections within individuals (75.2%; 204/271). Primaquine substantially reduced the proportion of participants experiencing recurrent infections attributable to probable relapse, from 57.3% to 1.7% in IMPROV and from 60.2% to 9.5% in OPRA. Polyclonal infection at enrolment was independently associated with increased odds of recurrence and a higher rate of probable relapse in OPRA, with a consistent but non-significant trend observed in IMPROV. These findings provide direct molecular evidence that the hypnozoite reservoir is the dominant driver of recurrent P. vivax infections in Ethiopia in the absence of radical cure. The marked reduction in probable relapse following primaquine treatment highlights the critical importance of expanding access to safe and effective radical cure strategies in Ethiopia and other comparable high-transmission settings.

Overview

CoChat Summary

TL;DR

Microhaplotype sequencing and Bayesian recurrence classification in two Ethiopian *P. vivax* trials show that, without primaquine, probable relapse dominates recurrent infections, while primaquine sharply reduces relapse-attributable recurrence. Polyclonal infection at enrolment was associated with higher recurrence and relapse risk in OPRA, with a non-significant trend in IMPROV.

Key findings

  • In the absence of primaquine, probable relapse was the dominant classification for primary recurrent infections in both trials (75.5%; 102/135) and for consecutive recurrent infections within individuals (75.2%; 204/271).
  • Primaquine substantially reduced the proportion of participants experiencing recurrent infections attributable to probable relapse, from 57.3% to 1.7% in IMPROV and from 60.2% to 9.5% in OPRA.
  • In OPRA non-primaquine arms, polyclonal infection at enrolment was associated with recurrence (74.0% vs 55.0%; OR = 2.35, 95% CI 1.14–4.83, p = 0.020) and a higher count of probable relapse episodes (ratio = 1.39, 95% CI 1.01–1.92, p = 0.044); IMPROV showed a consistent but non-significant trend (OR = 1.63, 95% CI 0.70–3.81, p = 0.26; relapse ratio = 1.14, 95% CI 0.61–2.14, p = 0.68).
  • Within-host identity-by-descent was lower in primaquine arms; for example, IMPROV control mean consecutive-pair IBD was 58% vs 23% in PQ arms (p = 1.1×10⁻⁵), and OPRA mean IBD was 75% in AL, 69% in CQ, and 55% in PQ arms (Kruskal-Wallis H = 9.5, p = 0.0086).

Methods

  • Microhaplotype genotyping used the vivaxGEN *P. vivax* 93-amplicon panel on parasite isolates collected at enrolment and subsequent recurrences over 12-month follow-up in two Ethiopian radical cure trials: IMPROV (604 samples from 444 participants) and OPRA (621 samples from 342 participants).
  • Within-host diversity was estimated with MOIRE effective multiplicity of infection (eMOI), pairwise relatedness with Dcifer identity-by-descent, and recurrence origin with the Pv3Rs Bayesian hierarchical model, which returned marginal posterior probabilities of relapse, reinfection, and recrudescence using time-window priors; relapse was classified as p(L) ≥ 0.75, reinfection as p(L) ≤ 0.25, and values between 0.25 and 0.75 as indeterminate.
  • Association between Day 0 clonality and recurrence or probable relapse was assessed with logistic regression restricted to non-primaquine control arms and fitted separately per trial.

Limitations

  • Stated: sampling bias because not every recurrence was genotyped; OPRA primaquine adherence was semi-supervised for the initial episode and unsupervised for subsequent recurrences, likely attenuating efficacy; the conservative reinfection prior (λ = 0.002/day) makes probable relapse estimates lower-bound.
  • Stated: the impact of polyclonality on classification could not be assessed robustly in IMPROV due to limited monoclonal pairs and more Pv3Rs computational failures; Pv3Rs’ two-parent assumption can misclassify half-siblings; fixed time-window priors were used, and a dedicated time-to-event model would allow more flexibility.
  • Evident from the text: transmission potential could not be directly assessed, and fully resolving genetic identity within polyclonal recurrences would require haplotype-deconvolved whole-genome data, which was beyond the study’s scope.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.64898/2026.11.12.765293

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC-BY · From the PDF
Image 2
CC-BY · From the PDF
Image 3
CC-BY · From the PDF
Image 4
CC-BY · From the PDF
Supplementary Figure S8: Impact of polyclonality at time of enrolment (Day 0) on likelihood of recurrence in IMPROV and OPRA. Monoclonal (eMOI ≤ 1.1); Polyclonal (eMOI > 1.1); 95% confidence interval (Wilson method).
Supplementary Figure S8: Impact of polyclonality at time of enrolment (Day 0) on likelihood of recurrence in IMPROV and OPRA. Monoclonal (eMOI ≤ 1.1); Polyclonal (eMOI > 1.1); 95% confidence interval (Wilson method).CC-BY · From the PDF
Image 6
CC-BY · From the PDF
perpetuity. It is made available under a CC-BY 4.0 International license. preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in bioRxiv preprint doi: https://doi.org/10.64898/2026.11.12.765293; this version posted November 13, 2026. The copyright holder for this
perpetuity. It is made available under a CC-BY 4.0 International license. preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in bioRxiv preprint doi: https://doi.org/10.64898/2026.11.12.765293; this version posted November 13, 2026. The copyright holder for thisCC-BY · From the PDF
Supplementary Figure S2: Assessing infection complexity across IMPROV and OPRA. (A) effective multiplicity of infection (eMOI) estimates compared to the mean number of alleles per locus by trial site. (B) eMOI compared to naive COI (the maximum number of alleles at any locus).
Supplementary Figure S2: Assessing infection complexity across IMPROV and OPRA. (A) effective multiplicity of infection (eMOI) estimates compared to the mean number of alleles per locus by trial site. (B) eMOI compared to naive COI (the maximum number of alleles at any locus).CC-BY · From the PDF
Supplementary Figure S3: Characterisation of the baseline genetic diversity of parasite populations across IMPROV and OPRA. (A) Distribution of eMOI posterior mean. (B) Allelic diversity, the mean number of distinct alleles per locus. (C) Pairwise relatedness (identity-by-descent) per site.
Supplementary Figure S3: Characterisation of the baseline genetic diversity of parasite populations across IMPROV and OPRA. (A) Distribution of eMOI posterior mean. (B) Allelic diversity, the mean number of distinct alleles per locus. (C) Pairwise relatedness (identity-by-descent) per site.CC-BY · From the PDF
Supplementary Figure S4: Identity-by-descent (IBD) network plot of baseline parasite populations within IMPROV and OPRA (IBD Thresholds [left to right]: 0.125, 0.25, 0.50, 0.95). (A) All Day 0 samples from IMPROV study sites: Arba Minch and Metehara. (B) All Day 0 samples from OPRA study sites: Batu and Bishoftu. (C) All Day 0 samples from both IMPROV and OPRA. (D) All monoclonal (eMOI ≤ 1.1) Day 0 samples from both IMPROV and OPRA.
Supplementary Figure S4: Identity-by-descent (IBD) network plot of baseline parasite populations within IMPROV and OPRA (IBD Thresholds [left to right]: 0.125, 0.25, 0.50, 0.95). (A) All Day 0 samples from IMPROV study sites: Arba Minch and Metehara. (B) All Day 0 samples from OPRA study sites: Batu and Bishoftu. (C) All Day 0 samples from both IMPROV and OPRA. (D) All monoclonal (eMOI ≤ 1.1) Day 0 samples from both IMPROV and OPRA.CC-BY · From the PDF
perpetuity. It is made available under a CC-BY 4.0 International license. preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in bioRxiv preprint doi: https://doi.org/10.64898/2026.11.12.765293; this version posted November 13, 2026. The copyright holder for this
perpetuity. It is made available under a CC-BY 4.0 International license. preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in bioRxiv preprint doi: https://doi.org/10.64898/2026.11.12.765293; this version posted November 13, 2026. The copyright holder for thisCC-BY · From the PDF
Image 12
CC-BY · From the PDF
Image 13
CC-BY · From the PDF
Image 14
CC-BY · From the PDF
Image 15
CC-BY · From the PDF
Image 16
CC-BY · From the PDF
Image 17
CC-BY · From the PDF
Image 18
CC-BY · From the PDF

Verification

Claims the paper makes

0 Valid · 0 Not valid · 41 Not checked · 144 Own results and interpretations

101 more claims

Create a free account to see all 185 claims and to verify the 71 references still open.

See all claims — free account
  • It may state two separate claims as one. 57
  • Probably not a substantial claim. 29
  • The quote only partly states this claim. 4

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Research works printed but not linked: 1

  1. Bakker JD. Mantel Test. 2026 [cited 27 Aug 2026]. Available: https://uw.pressbooks.pub/appliedmultivariatestatistics/chapter/mantel-test/

Cited by

Still being checked.

Metadata

Authors
Osborne, A. A., Ruybal-Pesantez, S., Rai, A., Trimarsanto, H., Hoon, K. S., Piera, K., Kleinecke, M., Rumaseb, A., Sutanto, E., Thriemer, K., Degaga, T. S., Hwang, J., Assefa, A., Woyessa, A., Hailu, A., Taylor, A., Day, N. P., Price, R. N., & Auburn, S.
Affiliations
  • Charles Darwin University (AU)
  • Barcelona Institute for Global Health, ISGlobal, Campus Clínic Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
  • Centers for Disease Control and Prevention (US)
  • University of North Carolina at Chapel Hill (US)
  • Ethiopian Public Health Institute (ET)
  • Institut Pasteur (FR)
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Mahidol University (TH)
Corresponding author
Osborne, Ashley A.
Venue
bioRxiv (Cold Spring Harbor Laboratory)
Publisher
openRxiv
Published
2026-11-13
OpenAlex
W7225986520
Cited by
0
References
36
Type
posted content
Language
en
Open access
Locations
bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion, cc-by)
Funders
National Health and Medical Research Council of Australia (Investigator Grant 2025377)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Immunology and Microbiology › Parasitology › Bird parasitology and diseases
  • Life Sciences › Immunology and Microbiology › Parasitology › Toxoplasma gondii Research Studies
Keywords
Plasmodium vivax, relapse, primaquine, radical cure, polyclonal infection, reinfection, recrudescence, Ethiopia, Bayesian hierarchical model

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.